Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-06-05

Clinical Trial Update: Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008) [Phase 1]

View source ↗

Summary

A Phase 1 multiple rising dose study of MK-6194 in participants with atopic dermatitis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MK-6194

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Dermatitis, Atopic | Phase 1 | Status: COMPLETED | Results posted: 2025-06-05